Absci (ABSI) Cash from Financing Activities (2020 - 2026)
Absci (ABSI) posted Cash from Financing Activities of $7.6 million for Q1 2026, up 96.67% sequentially from $3.8 million in Q4 2025, and down 82.34% YoY from $42.8 million in Q1 2025.
Absci (ABSI) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Absci has reported Cash from Financing Activities for 7 years, with the latest figure at $7.6 million in Q1 2026.
- Quarterly Cash from Financing Activities fell 82.34% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $70.7 million (up 60.21% YoY) and the FY2025 annual result came in at $105.9 million, up 28.38% from the prior year.
- Cash from Financing Activities improved to $7.6 million in Q1 2026 per ABSI's latest filing, from $3.8 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $81.2 million in Q1 2024 and troughed at -$1.2 million in Q4 2023.
- A 5-year average of $11.6 million and a median of $490000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 12209.59% in 2025, down 649.25% in 2025.
- Over 5 years, Cash from Financing Activities stood at $1.4 million in 2022, then slumped by 188.66% to -$1.2 million in 2023, then soared by 179.84% to $986000.0 in 2024, then soared by 289.66% to $3.8 million in 2025, then jumped by 96.67% to $7.6 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $7.6 million, $3.8 million, and $60.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Absci | 1.58 Bn | 1.37 Bn | - | 102.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 102.73 Mn |
| Jun 30, 2026 | 102.73 Mn |
| Mar 31, 2026 | 7.56 Mn |
| Mar 31, 2026 | 7.56 Mn |
| Dec 31, 2025 | 3.84 Mn |
| Dec 31, 2025 | 3.84 Mn |
| Sep 30, 2025 | 60.32 Mn |
| Sep 30, 2025 | 60.32 Mn |
| Jun 30, 2025 | -1.00 Mn |
| Jun 30, 2025 | -1.00 Mn |
| Mar 31, 2025 | 42.79 Mn |
| Mar 31, 2025 | 42.79 Mn |
| Dec 31, 2024 | 986,000.00 |
| Dec 31, 2024 | 986,000.00 |
| Sep 30, 2024 | 490,000.00 |
| Sep 30, 2024 | 490,000.00 |
| Jun 30, 2024 | -134,000.00 |
| Jun 30, 2024 | -134,000.00 |
| Mar 31, 2024 | 81.18 Mn |
| Mar 31, 2024 | 81.18 Mn |